[A26-57] Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-57
Commission:
Commission awarded on 29.05.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Adults with CD19+, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)
Result of dossier assessment:
- Adults with Philadelphia chromosome-positive, CD19+, relapsed or refractory B-cell precursor ALL in whom treatment with at least 2 tyrosine kinase inhibitors has failed and who have no alternative treatment options: added benefit not proven
- Adults with Philadelphia chromosome-negative, CD19+, relapsed or refractory B-cell precursor ALL: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-57